Andrew Johnson, MD
Medical Oncology · Gainesville, GANPI 1497045553
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,314 of the $22,244 with a category attached, or 77.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations.
Across 918 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Novartis$2K
- Seagen Inc.$2K
- Merck$1K
- Pfizer$1K
- Bristol Myers Squibb$866
- plus $12K from 54 others
Across 4 payments — averaging $57,483 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$219K
- Astrazeneca UK Limited$11K
What the payments were for
- Consulting fees$3,16814%
- Food & beverage$17,31478%
- Education$8824%
- Other$8814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,244 in reported general payments places this provider in the 75th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 46 | $685,604 |
| PomalystPomalidomide | 26 | $569,458 |
| TagrissoOsimertinib Mesylate | 28 | $462,778 |
| KisqaliRibociclib Succinate | 28 | $417,131 |
| RevlimidLenalidomide | 21 | $376,980 |
| XtandiEnzalutamide | 26 | $363,848 |
| BrukinsaZanubrutinib | 24 | $357,559 |
| NubeqaDarolutamide | 19 | $259,358 |
| ImbruvicaIbrutinib | 13 | $200,253 |
| Abiraterone Acetate | 14 | $107,715 |
| EliquisApixaban | 95 | $80,843 |
| XareltoRivaroxaban | 14 | $17,713 |
| Letrozole | 188 | $3,330 |
| Fentanyl | 38 | $3,296 |
| Enoxaparin Sodium | 12 | $2,909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $756 | $569,45826 claims |
| AstraZenecaTagrisso | $3,129 | $462,77828 claims |
| NovartisKisqali | $2,051 | $417,13128 claims |
| Bristol Myers SquibbRevlimid | $866 | $376,98021 claims |
| Astellas Pharma US IncXtandi | $373 | $363,84826 claims |
| Beigene USA, Inc.Brukinsa | $58 | $357,55924 claims |
| BayerNubeqa | $335 | $259,35819 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $401 | $200,25313 claims |
| PfizerEliquis | $1,163 | $80,84395 claims |
| Johnson & JohnsonXarelto | $825 | $17,71314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Gainesville
- Charles NashGainesville$19K
- Venumadhav KotlaGainesville$18K
- Yamin SunGainesville$17K
- Shravanti MacherlaGainesville$14K
- Timothy CareyGainesville$14K
- Devi SampatGainesville$13K
- Jennifer AndersonGainesville$12K
- Richard LociceroGainesville$9K
- Nancy SteadGainesville$2K
- Samir KhleifAugusta$337K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.